For decades, early-stage biotech and medtech companies operated on a familiar model: raise capital, advance the science, reach regulatory milestones, and trust that breakthrough innovation would ultimately justify the burn.
But in today’s market environment, Braeden Lichti, Chairman and founder of Northstrive Companies, says that equation is shifting.
“Increasingly, investors are asking a harder question: When a company’s primary asset is no longer its pipeline but its balance sheet, what is management’s obligation?”
He says there is an illusion in biotech that perseverance equals value creation. But public markets reward disciplined capital allocation, not blind continuation. When cash becomes the most valuable asset on the balance sheet, boards must reassess, revert course, and consider mergers, strategic alternatives, or returning capital to shareholders.
The Runway Reality
Clinical development is expensive. Regulatory setbacks are common. And for small-cap life sciences companies, operating losses can exceed $1 million per month without a guarantee of approval, reimbursement, or commercialization success.
“On paper, a company may appear financially strong showing millions in cash, no long-term debt, a healthy current ratio,” he says. “But if annual burn approaches half of available reserves, runway compresses quickly.”
In that scenario, Lichti says time becomes a strategic liability.
“Public markets have grown less tolerant of open-ended development cycles without clear catalysts. When a company trades at or below its net cash value, investors are sending a signal: the market is discounting the pipeline.”
And Lichti says this is what forces a governance reckoning.
“When companies reach a clinical or regulatory inflection point, boards typically face three options: continue investing in the pipeline, pursue strategic alternatives, or return capital to shareholders. Each route reflects a different philosophy about stewardship.”
The Shift From Growth to Discipline
Historically, life sciences boards leaned toward perseverance, sometimes masked as blind innovation. Scientific breakthroughs often require years of capital and patience. Investors understood that volatility came with the territory, but Lichti sees a change. In today’s environment, he’s seeing higher capital costs, tighter funding markets, and increased scrutiny of operating efficiency reshaping expectations.
“Shareholders are placing greater emphasis on capital preservation, dilution avoidance, defined timelines, and transparent milestone planning. Boards can no longer hide behind optimism. They must prove that continued spending creates more value than preserving cash.”
Activism Is No Longer Just About Control
Investor activism in biotech used to revolve around leadership changes or strategic pivots. Increasingly, it centers on capital allocation discipline.
The question is no longer simply, ‘Is the asset viable?’ It’s whether continued spending creates more value than preserving cash, pursuing a merger, or returning capital to shareholders
Lichti says the shift is overdue. Governance isn’t about preserving the vision. It’s about protecting shareholder capital.
Innovation vs. Obligation
None of this diminishes the importance of medical innovation. Breakthrough therapies still require risk, and patients still depend on companies willing to pursue difficult science.
But public companies operate within a dual mandate: advance innovation and protect shareholder value. “When those objectives diverge, boards must be willing to throw in the towel on a failing strategy rather than continue funding it at the expense of shareholders,” Lichti says. “When cash reserves become the company’s most tangible asset, the balance between those mandates grows more delicate.”
At certain moments, boards must decide whether capital is fuel for the next chapter or a value that should be preserved before it disappears.
“In today’s market, that decision is becoming more financially driven,” Lichti says, “and shareholders will demand it be confronted head-on.”
